BC Innovations | Dec 19, 2019
Distillery Therapeutics

Inhibiting the EIF4G1-EIF4E interaction to treat autism

DISEASE CATEGORY: Neurology INDICATION: Autism Disrupting the EIF4G1-EIF4E interaction could treat autism, a disorder characterized by social deficits and associated with increased dendritic spine densities and mutations in the E3 ligase complex component CUL3. In...
BC Innovations | Nov 15, 2017
Distillery Therapeutics

Neurology

INDICATION: Fragile X syndrome Mouse studies suggest inhibiting the eIF4E-eIF4G1 interaction could help treat fragile X syndrome. In a mouse model of fragile X syndrome, a tool compound that inhibits the eIF4E-eIF4G1 interaction increased dendritic...
BioCentury | Aug 15, 2016
Emerging Company Profile

Restraining translation

Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead...
Items per page:
1 - 3 of 3